Volume 19 Issue 2
Feb.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(2): 227-231
ZHU Xian-zhong, ZHANG Xian-nan, WANG Qin, ZHOU Ling. Prognosis of recurrent hepatocellular carcinoma patients after TACE combined with microwave ablation and analysis of prognosis-related predictive factors[J]. Chinese Journal of General Practice, 2021, 19(2): 227-231. doi: 10.16766/j.cnki.issn.1674-4152.001774
Citation: ZHU Xian-zhong, ZHANG Xian-nan, WANG Qin, ZHOU Ling. Prognosis of recurrent hepatocellular carcinoma patients after TACE combined with microwave ablation and analysis of prognosis-related predictive factors[J]. Chinese Journal of General Practice, 2021, 19(2): 227-231. doi: 10.16766/j.cnki.issn.1674-4152.001774
shu

Prognosis of recurrent hepatocellular carcinoma patients after TACE combined with microwave ablation and analysis of prognosis-related predictive factors

doi: 10.16766/j.cnki.issn.1674-4152.001774

  • Department of Ultrasound Medicine, Jinhua Guangfu Hospital, Jinhua, Zhejiang 321000, China

Funds:

 2020PY085

 2018-3-001C

  • Received Date: 2020-03-18
    Available Online: 2022-02-19
    Abstract
  •   Objective  To explore the prognosis of recurrent hepatocellular carcinoma patients after transcatheter arterial chemoembolisation (TACE) combined with microwave ablation (MWA) and its related factors, constructing a prognostic nomogram concerning overall survival.  Methods  Retrospective analysis was performed on clinical data from recurrent hepatocellular carcinoma patients (82 cases) treated by TACE-MWA in our hospital from January 2015 to January 2017. The patients were divided into progress, non-progress, survival, and death groups depending on disease progression and survival. The progression and survival situation during 2 years of follow-up were recorded, and the related factors for both were analysed. A prognostic nomogram was then constructed.  Results  The overall survival of patients in the two years after TACE-MWA was 68.29%, and the progression-free survival rate was 36.59%. The preoperative AFP level, tumour number, and largest tumour diameter in the progress group were higher than those in the non-progress group (all P < 0.05). The largest tumour diameter, cases with tumour close to hepatic hilum < 2 cm, and preoperative AFP level in the death group were higher than those in the survival group (all P < 0.05). Statistical differences were observed between the two groups in terms of Child-Pugh classification and BCLC classification (all P < 0.05). The preoperative AFP level, tumour number, and largest tumour diameter (HR=1.026, 51.487, 2.463; P=0.024, 0.047, 0.016, respectively) were the risk factors of recurrent hepatocellular carcinoma patients' progression-free survival. Preoperative AFP level, largest tumour diameter, and tumour proximity to hepatic hilum < 2 cm (HR=1.012, 1.189, 8.479; P=0.002, 0.011, 0.021, respectively) were the risk factors of recurrent hepatocellular carcinoma patients' overall survival. The consistency index for predicting patients' overall survival in two years was 0.919 (95% CI: 0.885-0.946).  Conclusion  Emphasising on factors such as tumour number, size, and location has certain meaning for predicting the progression-free survival and overall survival of hepatocellular carcinoma patients after TACE-MWA.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    杨绍梅, 张娜. 肝癌治疗药物的研究进展[J]. 中国新药与临床杂志, 2015, 34(2): 93-98. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL201502003.htm
    [2]
    HIROKAWA F, HAYASHI M, ASAKUMA M, et al. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma[J]. Surg Oncol, 2016, 25(1): 24-29. doi: 10.1016/j.suronc.2015.12.002
    [3]
    DI COSTANZO G G, TORTORA R, D'ADAMO G, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: A randomized trial[J]. J Gastroenterol Hepatol, 2015, 30(3): 559-565. doi: 10.1111/jgh.12791
    [4]
    YOON S M, RYOO B Y, LEE S J, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018, 4(5): 661-669. doi: 10.1001/jamaoncol.2017.5847
    [5]
    CHANG L, WANG Y, ZHANG J, et al. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies[J]. Oncotarget, 2017, 8(12): 20418-20427. doi: 10.18632/oncotarget.14668
    [6]
    LI W, MAN W, GUO H, et al. Clinical study of transcatheter arterial chemoembolization combined with microwave ablation in the treatment of advanced hepatocellular carcinoma[J]. J Cancer Res Ther, 2016, 12(Supplement): C217-C220. http://europepmc.org/abstract/MED/28230020
    [7]
    郭欢庆, 闫鹏, 邹常咏, 等. TACE联合微波消融治疗大肝癌的初步研究[J]. 实用放射学杂志, 2015, 31(10): 1692-1694, 1730. doi: 10.3969/j.issn.1002-1671.2015.10.030
    [8]
    SUN A, CHENG Z, WU P, et al. Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation[J]. World J Gastroenterol, 2015, 21(10): 2997-3004. doi: 10.3748/wjg.v21.i10.2997
    [9]
    李前进, 刘兴贵. 肝癌晚期患者氩氦刀治疗手术前后外周血T、NK细胞表达差异相关研究[J]. 贵州医药, 2015, 39(8): 706-707. doi: 10.3969/j.ISSN.1000-744X.2015.08.010
    [10]
    白涛, 叶甲舟, 陈洁, 等. TACE联合RFA治疗复发性肝癌的生存期分析[J]. 肿瘤学杂志, 2018, 24(8): 779-782. https://www.cnki.com.cn/Article/CJFDTOTAL-XHON201808007.htm
    [11]
    SI Z M, WANG G Z, QIAN S, et al. Combination therapies in the management of large (≥5 cm) hepatocellular carcinoma: microwave ablation immediately followed by transarterial chemoembolization[J]. J Vasc Interv Radiol, 2016, 27(10): 1577-1583. doi: 10.1016/j.jvir.2016.02.014
    [12]
    SAUZAY C, PETIT A, BOURGEOIS A, et al. Alpha-foetoprotein(AFP): A multi-purpose marker in hepatocellular carcinoma[J]. Clin Chim Acta, 2016, 463(12): 39-44. http://www.sciencedirect.com/science/article/pii/S000989811630403X
    [13]
    甘雨, 田娜娜, 陈华辉, 等. 原发性肝癌患者AFP浓度与临床特点及预后的相关性[J]. 中华肿瘤防治杂志, 2016, 23(14): 958-962. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201614012.htm
    [14]
    赵鹏, 郑加生, 张洪海, 等. 肝动脉导管化疗栓塞联合CT引导精准微波消融治疗原发性肝癌的疗效及影响因素[J]. 中华肿瘤杂志, 2016, 38(2): 138-145. doi: 10.3760/cma.j.issn.0253-3766.2016.02.012
    [15]
    李蕊利, 万娟. 原发性肝癌射频消融预后的影响因素分析[J]. 现代肿瘤医学, 2015, 23(20): 2970-2972. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201520029.htm
    [16]
    MEHTA N, HEIMBACH J, HARNOIS D M, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA Oncol, 2017, 3(4): 493-500. doi: 10.1001/jamaoncol.2016.5116
    [17]
    BIEDERMAN D M, TITANO J J, BISHAY V L, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study[J]. Radiology, 2017, 283(3): 895-905. doi: 10.1148/radiol.2016160718
    [18]
    ABDELAZIZ AO, NABEEL M M, ELBAZ T M, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis[J]. Scand J Gastroenterol, 2015, 50(4): 479-484. doi: 10.3109/00365521.2014.1003397
    [19]
    FARSAD K, COSTENTIN C E, ZHU A X. Hepatocellular carcinoma with portal venous invasion: radiating new hope?[J]. JAMA Oncol, 2018, 4(5): 669-670. doi: 10.1001/jamaoncol.2018.0007
    [20]
    YUAN Z H, WANG Y, HU C X, et al. Efficacy of percutaneous thermal ablation combined with transarterial embolization for recurrent hepatocellular carcinoma after hepatectomy and a prognostic nomogram to predict survival[J]. Technol Cancer Res Treat, 2018, 17(8): 1-13. http://www.ncbi.nlm.nih.gov/pubmed/30244651
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (172) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return